Hashimoto's thyroiditis

What it is

Hashimoto's thyroiditis is the most common cause of hypothyroidism in iodine-sufficient countries, affecting roughly 5% of adults and occurring 7–10 times more often in women than men. Also called chronic lymphocytic thyroiditis or Hashimoto's disease, it is an autoimmune condition in which the immune system progressively attacks and destroys thyroid tissue, eventually impairing the gland's ability to produce thyroid hormones (T3 and T4). It is the leading autoimmune thyroid condition worldwide and the most common explanation for an elevated TSH on routine bloodwork in Canada.

The condition typically presents between ages 30 and 50, though it can appear at any age. It runs in families and frequently co-occurs with other autoimmune conditions — type 1 diabetes, rheumatoid arthritis, and lupus among them. In Canada, thyroid function testing is widely available through LifeLabs and Dynacare, and levothyroxine (the standard treatment) is covered under most provincial drug benefit programs, including Ontario's ODB and BC PharmaCare.

Hashimoto's follows a slow, variable course. Many people carry the diagnosis for years before developing overt hypothyroidism. A small number experience a transient hyperthyroid phase early in the disease. With appropriate monitoring and treatment, the condition is very effectively managed and does not shorten life expectancy.

Causes and mechanism

Hashimoto's arises from a combination of genetic susceptibility and environmental triggers. The immune system produces antibodies — most commonly thyroid peroxidase antibodies (TPO-Ab) and thyroglobulin antibodies (TG-Ab) — that target thyroid tissue. Simultaneously, T-lymphocytes infiltrate the gland, causing chronic inflammation (lymphocytic thyroiditis) and progressive destruction of the thyroid follicles that produce hormone.

As follicles are destroyed, T4 and T3 output falls. The pituitary gland compensates by releasing more thyroid-stimulating hormone (TSH), but over time the damaged gland cannot respond adequately, and overt hypothyroidism develops.

Established contributing factors include:

• Genetics — specific HLA gene variants increase susceptibility; a first-degree relative with autoimmune thyroid disease meaningfully raises personal risk
• Female sex — the strong female predominance points to a role for estrogen in modulating immune tolerance in genetically susceptible individuals
• Iodine excess — very high iodine intake can trigger or accelerate autoimmune thyroid disease in predisposed people
• Selenium deficiency — selenium is required for thyroid hormone metabolism and helps protect thyroid tissue from oxidative damage
• Postpartum period, infection, and psychological stress — each can precipitate or worsen autoimmune thyroid activity

Symptoms and diagnosis

Hashimoto's progresses slowly. Early on, there may be no symptoms at all, or occasionally a brief hyperthyroid phase called Hashitoxicosis, in which stored hormone leaks from the inflamed gland. As the disease advances toward hypothyroidism, symptoms accumulate:

• Persistent fatigue and sluggishness
• Weight gain without dietary change
• Cold intolerance
• Dry skin, brittle nails, hair thinning or loss
• Constipation and slowed heart rate
• Low mood, brain fog, difficulty concentrating
• Muscle aches and stiffness
• Heavy or irregular menstrual periods
• Facial or peripheral puffiness (myxoedema in severe cases)
• Goitre (thyroid enlargement) — present in some but not all cases

Diagnostic workup typically includes:

Test	What it shows	Notes
TSH	Elevated = thyroid underperforming	Primary screening test
Free T4	Low or low-normal	Confirms overt hypothyroidism
TPO-Ab	Positive in ~90% of cases	Confirms autoimmune origin
TG-Ab	Positive in a further subset	Useful when TPO-Ab negative
Thyroid ultrasound	Heterogeneous, reduced echogenicity	Supports diagnosis; not always required

A positive TPO-Ab with an elevated TSH is sufficient to diagnose Hashimoto's with hypothyroidism in most clinical settings. Ultrasound adds detail but is not mandatory for every patient.

Treatment options

There is currently no treatment that reverses the underlying autoimmune process. The consequences — primarily hypothyroidism — are, however, very effectively managed.

Levothyroxine (synthetic T4) is the standard treatment once hypothyroidism is confirmed. Taken as a once-daily tablet on an empty stomach, it restores circulating T4 to normal and resolves most symptoms. Dosing is individualized and adjusted based on TSH levels, symptoms, age, and weight. Most patients require lifelong therapy. In Canada, brand-name (Synthroid, Eltroxin) and generic levothyroxine are both available; provincial formularies generally cover the generic.

Combination T4/T3 therapy — adding liothyronine (T3) or switching to desiccated thyroid extract (DTE, which contains both T4 and T3) — is considered in the minority of patients who remain symptomatic despite a normalized TSH on levothyroxine alone. This approach is not first-line and requires careful monitoring.

Watchful waiting is appropriate for patients with positive antibodies but normal thyroid function (subclinical Hashimoto's). Annual TSH monitoring is recommended rather than pre-emptive treatment, since not all will progress to overt hypothyroidism.

Nutritional considerations: Selenium supplementation has the strongest evidence among dietary interventions, with trials showing reductions in TPO-Ab levels and some protection of thyroid tissue. Iodine should be neither deficient nor excessive. A gluten-free diet may reduce antibody levels in patients who also have confirmed coeliac disease, but evidence in Hashimoto's without coeliac disease remains inconclusive.

When to see a clinician in Canada

Seek assessment from a family physician or nurse practitioner if you have persistent, unexplained fatigue, weight gain, cold intolerance, hair loss, low mood, or heavy periods — particularly if you have a personal or family history of autoimmune disease. A visible or palpable swelling at the front of the neck warrants prompt evaluation.

In Canada, initial assessment and TSH testing are available through primary care. Endocrinology referral is typically reserved for complex cases: persistent symptoms despite optimized levothyroxine, consideration of combination T4/T3 therapy, pregnancy planning, or an uncertain diagnosis. Canadians seeking virtual thyroid assessment can access licensed prescribers through platforms such as Maple, Felix, Cleo, Phoenix, or others — though ongoing monitoring still benefits from in-person bloodwork at a LifeLabs or Dynacare collection site.

Limitations and open questions

Research is still emerging on several aspects of Hashimoto's management. The benefit of combination T4/T3 therapy over levothyroxine monotherapy remains debated; randomized trial results are mixed, and neither the American Thyroid Association nor the SOGC currently recommends it as routine first-line care. The role of selenium supplementation in meaningfully altering disease progression — rather than just antibody titres — has not been definitively established. Evidence for a gluten-free diet in Hashimoto's patients without coeliac disease is preliminary and based largely on small studies. The threshold TSH at which to initiate levothyroxine in subclinical hypothyroidism (particularly in older adults) remains an area of active clinical debate. Health Canada has not issued specific guidance on dietary supplementation for autoimmune thyroid conditions. The long-term risk of thyroid lymphoma associated with Hashimoto's is real but very low, and routine surveillance imaging is not currently standard practice in Canada.